Coherus BioSciences: A High-Stakes Pivot from Biosimilars to Immuno-Oncology with Boom-or-Bust Potential
Overview
Coherus BioSciences has undergone a dramatic transformation, divesting its biosimilar franchises and pivoting towards novel immuno-oncology therapies with a rebrand as Coherus Oncology. Founded in 2010, it was previously reliant on biosimilars UDENYCA (for neutropenia) and CIMERLI (for retinal diseases). Both franchises were sold in 2024/25, with UDENYCA exiting in a $558M deal and CIMERLI sold for $170M. The company now has a sole marketed immunotherapy, Loqtorzi (toripalimab), focused on NPC, and is developing a portfolio of innovative cancer immunotherapies (notably anti-IL-27 and anti-CCR8 antibodies). Coherus’s core commercial presence and value proposition are now centered exclusively on oncology, targeting both head & neck cancers and broader solid tumor immunotherapy opportunities. This pivot marks a high-risk inflection point, as the company's ongoing revenues hinge on the success of a single new agent and unproven pipeline, transitioning away from the once stable biosimilar cash flows.